Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05MBZ
|
|||
| Former ID |
DAP000086
|
|||
| Drug Name |
Tamsulosin
|
|||
| Synonyms |
Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Benign prostatic hyperplasia [ICD-11: GA90; ICD-10: N40; ICD-9: 600] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Yamanouchi Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H28N2O5S
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
|
|||
| InChI |
1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
|
|||
| InChIKey |
DRHKJLXJIQTDTD-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 106133-20-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9334, 7978548, 10242264, 14855214, 14855215, 29308096, 46507763, 48416590, 49658919, 49881530, 50112696, 57342917, 77491402, 92309311, 93166419, 94568973, 96025245, 103219988, 103956570, 104369951, 117870725, 118048890, 124772213, 124893313, 126662035, 127253628, 127253629, 127253630, 127253631, 127253632, 127253633, 127253634, 127775697, 131293768, 131322925, 131549270, 134223415, 134337414, 135047731, 135651350, 137001370, 142769217, 143493354, 152164201, 152235887, 160826144, 160964050, 163092709, 163388355, 164786761
|
|||
| ChEBI ID |
CHEBI:9398
|
|||
| ADReCS Drug ID | BADD_D02113 ; BADD_D02114 | |||
| SuperDrug ATC ID |
G04CA02
|
|||
| SuperDrug CAS ID |
cas=106133204
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1A (ADRA1A) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| AMPK signaling pathway | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 488). | |||
| REF 2 | Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.